entertainment -WSS

entertainment

author：focus 2025-10-02 09:47:23 - browse：8549

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Bird flu surveillance in wastewater gets boost from consortium

leisure time

WSS

FDA poised to publish guidelines for clinical trial diversity

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

HHS names first

DeSantis can now import cheaper drugs. But will Biden get credit?

Three issues to watch in global health in 2024

Addressing health care workers' trauma can help fight burnout

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

HHS names first

Affirmative action in medical school literally saved lives

ASCO eve: Let’s set the table for this year's meeting

How to save PrEP access — and even expand it

H5N1 bird flu outbreak: Second human case reported, in Michigan

Supreme Court strikes down use of affirmative action

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Moonlake's readout produced a cash windfall. Risks remain

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Wikipedia

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Cue Health, Covid

Reports of telehealth's death have been greatly exaggerated

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Cue Health, Covid

Digital health: a case of mistaken identity

knowledge

leisure time

hotspot

explore